Literature DB >> 20625009

Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis.

Harald F Langer1, Kyoung-Jin Chung, Valeria V Orlova, Eun Young Choi, Sunil Kaul, Michael J Kruhlak, Markella Alatsatianos, Robert A DeAngelis, Paul A Roche, Paola Magotti, Xuri Li, Matina Economopoulou, Stavros Rafail, John D Lambris, Triantafyllos Chavakis.   

Abstract

Beyond its role in immunity, complement mediates a wide range of functions in the context of morphogenetic or tissue remodeling processes. Angiogenesis is crucial during tissue remodeling in multiple pathologies; however, the knowledge about the regulation of neovascularization by the complement components is scarce. Here we studied the involvement of complement in pathological angiogenesis. Strikingly, we found that mice deficient in the central complement component C3 displayed increased neovascularization in the model of retinopathy of prematurity (ROP) and in the in vivo Matrigel plug assay. In addition, antibody-mediated blockade of C5, treatment with C5aR antagonist, or C5aR deficiency in mice resulted in enhanced pathological retina angiogenesis. While complement did not directly affect angiogenesis-related endothelial cell functions, we found that macrophages mediated the antiangiogenic activity of complement. In particular, C5a-stimulated macrophages were polarized toward an angiogenesis-inhibitory phenotype, including the up-regulated secretion of the antiangiogenic soluble vascular endothelial growth factor receptor-1. Consistently, macrophage depletion in vivo reversed the increased neovascularization associated with C3- or C5aR deficiency. Taken together, complement and in particular the C5a-C5aR axes are potent inhibitors of angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20625009      PMCID: PMC2996109          DOI: 10.1182/blood-2010-01-261503

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  58 in total

1.  Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a.

Authors:  A M Finch; A K Wong; N J Paczkowski; S K Wadi; D J Craik; D P Fairlie; S M Taylor
Journal:  J Med Chem       Date:  1999-06-03       Impact factor: 7.446

Review 2.  Immunological mechanisms in the pathogenesis of diabetic retinopathy.

Authors:  Anthony P Adamis; Adrienne J Berman
Journal:  Semin Immunopathol       Date:  2008-03-14       Impact factor: 9.623

Review 3.  Role of myeloid cells in tumor angiogenesis and growth.

Authors:  Farbod Shojaei; Cuiling Zhong; Xiumin Wu; Lanlan Yu; Napoleone Ferrara
Journal:  Trends Cell Biol       Date:  2008-07-07       Impact factor: 20.808

4.  The C5a chemoattractant receptor mediates mucosal defence to infection.

Authors:  U E Höpken; B Lu; N P Gerard; C Gerard
Journal:  Nature       Date:  1996-09-05       Impact factor: 49.962

5.  Recombinant C5a stimulates transcription rather than translation of interleukin-1 (IL-1) and tumor necrosis factor: translational signal provided by lipopolysaccharide or IL-1 itself.

Authors:  R Schindler; J A Gelfand; C A Dinarello
Journal:  Blood       Date:  1990-10-15       Impact factor: 22.113

6.  Genetic disruption of the murine complement C3 promoter region generates deficient mice with extrahepatic expression of C3 mRNA.

Authors:  A Circolo; G Garnier; W Fukuda; X Wang; T Hidvegi; A J Szalai; D E Briles; J E Volanakis; R A Wetsel; H R Colten
Journal:  Immunopharmacology       Date:  1999-05

7.  Biologically active conformer of the effector region of human C5a and modulatory effects of N-terminal receptor binding determinants on activity.

Authors:  A M Finch; S M Vogen; S A Sherman; L Kirnarsky; S M Taylor; S D Sanderson
Journal:  J Med Chem       Date:  1997-03-14       Impact factor: 7.446

8.  Conformational analysis of COOH-terminal segments of human C3a. Evidence of ordered conformation in an active 21-residue peptide.

Authors:  Z X Lu; K F Fok; B W Erickson; T E Hugli
Journal:  J Biol Chem       Date:  1984-06-25       Impact factor: 5.157

9.  Oxygen-induced retinopathy in the mouse.

Authors:  L E Smith; E Wesolowski; A McLellan; S K Kostyk; R D'Amato; R Sullivan; P A D'Amore
Journal:  Invest Ophthalmol Vis Sci       Date:  1994-01       Impact factor: 4.799

10.  Del-1, an endogenous leukocyte-endothelial adhesion inhibitor, limits inflammatory cell recruitment.

Authors:  Eun Young Choi; Emmanouil Chavakis; Marcus A Czabanka; Harald F Langer; Line Fraemohs; Matina Economopoulou; Ramendra K Kundu; Alessia Orlandi; Ying Yi Zheng; Darue A Prieto; Christie M Ballantyne; Stephanie L Constant; William C Aird; Thalia Papayannopoulou; Carl G Gahmberg; Mark C Udey; Peter Vajkoczy; Thomas Quertermous; Stefanie Dimmeler; Christian Weber; Triantafyllos Chavakis
Journal:  Science       Date:  2008-11-14       Impact factor: 47.728

View more
  83 in total

Review 1.  Complement genetics, deficiencies, and disease associations.

Authors:  Karine R Mayilyan
Journal:  Protein Cell       Date:  2012-07-10       Impact factor: 14.870

Review 2.  Targeted complement inhibition and microvasculature in transplants: a therapeutic perspective.

Authors:  M A Khan; J L Hsu; A M Assiri; D C Broering
Journal:  Clin Exp Immunol       Date:  2015-11-05       Impact factor: 4.330

Review 3.  Complement activation in the context of stem cells and tissue repair.

Authors:  Ingrid U Schraufstatter; Sophia K Khaldoyanidi; Richard G DiScipio
Journal:  World J Stem Cells       Date:  2015-09-26       Impact factor: 5.326

4.  Correlation of perfusion parameters with genes related to angiogenesis regulation in glioblastoma: a feasibility study.

Authors:  R Jain; L Poisson; J Narang; L Scarpace; M L Rosenblum; S Rempel; T Mikkelsen
Journal:  AJNR Am J Neuroradiol       Date:  2012-03-15       Impact factor: 3.825

5.  Endogenous developmental endothelial locus-1 limits ischaemia-related angiogenesis by blocking inflammation.

Authors:  Anne Klotzsche-von Ameln; Sebastian Cremer; Jedrzej Hoffmann; Peggy Schuster; Sherif Khedr; Irina Korovina; Maria Troullinaki; Ales Neuwirth; David Sprott; Antonios Chatzigeorgiou; Matina Economopoulou; Alessia Orlandi; Andreas Hain; Andreas M Zeiher; Andreas Deussen; George Hajishengallis; Stefanie Dimmeler; Triantafyllos Chavakis; Emmanouil Chavakis
Journal:  Thromb Haemost       Date:  2017-04-27       Impact factor: 5.249

Review 6.  Obesity "complements" preeclampsia.

Authors:  Kelsey N Olson; Leanne M Redman; Jenny L Sones
Journal:  Physiol Genomics       Date:  2019-02-04       Impact factor: 3.107

7.  The complement anaphylatoxin C5a receptor contributes to obese adipose tissue inflammation and insulin resistance.

Authors:  Julia Phieler; Kyoung-Jin Chung; Antonios Chatzigeorgiou; Anne Klotzsche-von Ameln; Ruben Garcia-Martin; David Sprott; Maria Moisidou; Theodora Tzanavari; Barbara Ludwig; Elena Baraban; Monika Ehrhart-Bornstein; Stefan R Bornstein; Hassan Mziaut; Michele Solimena; Katia P Karalis; Matina Economopoulou; John D Lambris; Triantafyllos Chavakis
Journal:  J Immunol       Date:  2013-09-16       Impact factor: 5.422

8.  Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization.

Authors:  Selene Nunez-Cruz; Phyllis A Gimotty; Matthew W Guerra; Denise C Connolly; You-Qiang Wu; Robert A DeAngelis; John D Lambris; George Coukos; Nathalie Scholler
Journal:  Neoplasia       Date:  2012-11       Impact factor: 5.715

Review 9.  The dual role of complement in cancer and its implication in anti-tumor therapy.

Authors:  Ioannis Kourtzelis; Stavros Rafail
Journal:  Ann Transl Med       Date:  2016-07

10.  A novel role of complement in retinal degeneration.

Authors:  Minzhong Yu; Weilin Zou; Neal S Peachey; Thomas M McIntyre; Jinbo Liu
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-11-19       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.